Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
Methylphenidate and dexamfetamine are now funded for up to three months’ supply when prescribed through the New Zealand ePrescription Service (NZePS). Read this microlearning to find out more.
This page provides the specific methodology used for each data story featured in EPiC Youth mental health.
This editable PDF helps you to delve into the EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions.
*New audit section*
An additional audit/CQI section allows you or your practice team to repeat the process, completing activities that may be used for Foundation Standard or the Cornerstone CQI or Equity modules.
Triazolam tablets have been delisted, with stocks of both 125mcg and 250mcg tablets likely to have run out. Patients who take triazolam regularly will need to be withdrawn slowly, or changed to alternative medicine if continued treatment is necessary.
Immune-related adverse events are common with ICI therapy, can be serious, and can occur up to 90 days after the last dose. Therefore, it's important to be able to recognise signs and symptoms of adverse events in primary care. Our new resource supports you to do this.
Our free Continuous Quality Improvement Toolkit can help you to complete the Cornerstone CQI module, fulfill Foundation Standard criteria, make the most of the EPiC dashboard, and change practices that may be contributing to health inequities.
Liraglutide (Victoza brand only) joins dulaglutide as a funded GLP-1 receptor agonist for treating type 2 diabetes. This piece of microlearning outlines the differences and similarities between the two medicines.
Phenobarbitone tablets are undergoing a brand change. In order to transition patients with epilepsy to the new brand safely, action is required as soon as practicable by both the healthcare professional and patient
Manage patient expectations for antibiotics with our Virus Action Plans for adults and children. These concise, editable information sheets help to reinforce when symptomatic and supportive care is the best medicine for your patient.
Available in Arabic, English, Māori, Hindi, Samoan, simplified Chinese and Tongan.
This piece of microlearning quotes results from the Youth19 Rangatahi Smart Survey, which shows that depression rates among young New Zealanders have risen.
For uncomplicated lower UTIs, often referred to as cystitis, using the right antibiotic for the right duration is the best way to ensure appropriate, effective treatment and avoid development of antimicrobial resistance. This case study illustrates the recommended treatment for a symptomatic, uncomplicated UTI.
On 1 March 2023, liraglutide (Victoza brand) became the second GLP-1 receptor agonist (GLP1RA) funded in Aotearoa New Zealand. This article and accompanying algorithm PDF have been developed to help prescribers through the process of starting dulaglutide or liraglutide in eligible patients with type 2 diabetes.